Therapeutic Area: Immunology Product Name: Diregura
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: LTL Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).